The Company believes that its capital structure remains in a stable condition following its comprehensive refinancing in May 2023. The Company also believes it has sufficient liquidity to achieve its strategic plan over the next 12 months as of the date hereof. During fiscal year 2024, Lifecore completed the following liquidity and business update matters which are included in the preliminary unaudited historical financial data above and were disclosed as subsequent events in the Company’s 2023 Annual Report on Form 10-K. Lifecore successfully entered into an amended and restated supply agreement with one of its customers which provided revised pricing and payment of a $5 million working capital deposit which was received in December 2023. The Company also made significant progress in clearing up former business dealings associated with its since divested Curation Foods segment, including: $2.7 million of cash proceeds from its sale of O Olive, receipt of a $1.85 million insurance settlement, and $0.9 million in settlement of a note receivable from a former supplier.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- LFCR Upcoming Earnings Report: What to Expect?
- Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
- Lifecore Biomedical Announces New CEO and Equity Inducement Plan
- Lifecore concludes strategic review, announces management, board changes
- Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes